Molecular Subtypes of Multimorbidity: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies

Abstract

Multimorbidity, defined as the co-occurrence of two or more chronic diseases in an individual, presents a significant challenge for modern healthcare. Recent advances in molecular medicine have revealed that multimorbidity is not a uniform clinical entity but comprises distinct molecular subtypes with unique pathophysiological mechanisms, risk profiles, and therapeutic responses. This review synthesizes current evidence regarding the epidemiology, pathophysiology, risk factors, clinical features, diagnosis, management, and emerging therapies for molecular subtypes of multimorbidity, with an emphasis on integrating recent guideline recommendations and translational research findings relevant to clinical practice.

Introduction

Multimorbidity is a growing concern in aging populations worldwide, complicating disease management and increasing healthcare costs. Traditional approaches have focused on individual diseases; however, recent research highlights the heterogeneity within multimorbidity syndromes, driven by underlying molecular and genetic differences. Understanding these molecular subtypes enables precision medicine approaches, improving patient outcomes by tailoring interventions to specific pathobiological profiles.

Epidemiology / Disease Burden

The prevalence of multimorbidity exceeds 60% in adults over 65, with a rising incidence in younger populations due to lifestyle and environmental factors. Epidemiological studies, such as those from the UK Biobank and large European cohorts, have characterized distinct clusters of co-occurring diseases (e.g., cardiometabolic, neuropsychiatric, and inflammatory clusters) that often share molecular signatures. These subtypes contribute disproportionately to disability-adjusted life years (DALYs) and health resource utilization, underlining the need for molecular stratification in clinical care and public health planning.

Pathophysiology

Molecular subtyping of multimorbidity leverages omics technologies—genomics, transcriptomics, proteomics, and metabolomics—to identify shared and divergent pathways among coexisting diseases. For example, cardiometabolic multimorbidity often involves dysregulation of inflammatory cytokines, insulin signaling, and lipid metabolism, while neuropsychiatric multimorbidity may be characterized by alterations in neurotransmitter pathways and neuroinflammation. Epigenetic changes, mitochondrial dysfunction, and cellular senescence are common mechanisms, and multi-omics analyses have revealed distinct molecular signatures even among patients with similar clinical presentations, suggesting the importance of molecular phenotyping for risk stratification and therapy selection.

Risk Factors

Risk factors for specific molecular subtypes of multimorbidity extend beyond traditional demographic and lifestyle variables. Genetic predispositions, such as polymorphisms in inflammatory genes (e.g., IL6, CRP), metabolic regulators (e.g., FTO, TCF7L2), and neurotrophic factors (e.g., BDNF), modulate susceptibility to clustered diseases. Environmental exposures, including air pollution, diet, and physical inactivity, interact with genetic risk to promote distinct molecular trajectories. Recent findings also implicate the gut microbiome and its metabolites as modulators of systemic inflammation and metabolic health, contributing to the development of specific multimorbidity profiles.

Clinical Features

Clinically, patients with molecularly defined multimorbidity subtypes often present with overlapping yet distinct symptomatology, disease progression, and complications. For instance, individuals with an inflammatory molecular subtype may exhibit persistent fatigue, polyarthralgia, and elevated C-reactive protein, while those with a metabolic subtype may demonstrate central obesity, insulin resistance, and dyslipidemia. Recognizing these patterns facilitates early intervention and targeted screening. Importantly, molecular subtyping can help distinguish between primary disease drivers and secondary manifestations, refining clinical phenotyping and management strategies.

Diagnosis

Diagnosis of molecular subtypes of multimorbidity now incorporates advanced biomarker panels, genetic testing, and machine learning algorithms for patient stratification. Multi-omics profiling—using blood, tissue, or microbiome samples—enables clinicians to identify patients with high-risk molecular signatures, guiding personalized surveillance and intervention. Integrated diagnostic frameworks, such as the use of transcriptomic risk scores in cardiovascular and metabolic multimorbidity, are increasingly available in research settings, with translation to clinical practice anticipated in the near future.

Treatment & Management

Management of multimorbidity requires a shift from single-disease guidelines to holistic, patient-centered care. For molecular subtypes, treatment regimens are informed by the underlying pathobiology. Anti-inflammatory agents, metabolic modulators, and neuroprotective drugs are matched to the dominant molecular pathways. Polypharmacy risks are mitigated through rational drug selection and pharmacogenomic profiling. Multidisciplinary care teams, including genetic counselors and molecular pathologists, optimize therapeutic strategies based on individual molecular profiles, improving adherence and reducing adverse events.

Recent Advances / Emerging Therapies

Recent advances include targeted biologics (e.g., IL-6 inhibitors for inflammatory subtypes), SGLT2 inhibitors and GLP-1 receptor agonists for cardiometabolic clusters, and microbiome-modulating interventions. Gene editing and RNA-based therapies are under investigation for selected genetic subtypes. Artificial intelligence platforms now integrate multi-omics data to predict disease trajectories and treatment responses, enabling dynamic, adaptive care pathways. Early-phase clinical trials of combination therapies targeting multiple molecular pathways have shown promise in reducing disease burden and improving quality of life.

Guideline Recommendations

Current guidelines from bodies such as the European Society of Cardiology and American College of Physicians advocate for routine assessment of multimorbidity in clinical practice, with emerging recommendations to incorporate molecular profiling into risk stratification and management where available. The integration of omics-informed care is encouraged in research settings and specialized centers, with ongoing efforts to develop standardized protocols for molecular subtyping, data sharing, and clinical decision support.

Conclusion

Molecular subtypes of multimorbidity represent a paradigm shift in understanding, diagnosing, and managing complex chronic disease clusters. Advances in omics technologies and precision medicine offer opportunities for personalized, mechanism-based care that addresses the heterogeneity of multimorbidity. Continued research, interdisciplinary collaboration, and translation of molecular insights into clinical guidelines are essential for realizing the full potential of this approach and improving outcomes for patients with multiple chronic conditions.